Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors (NCT05462717)
π©Ί Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (6 items).
Location: Highlands Oncology Group β Springdale, Arkansas
π "Do I Qualify?" β 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Primary central nervous system (CNS) tumors
- Active brain metastases
- Known impairment of GI function that would alter the absorption
- Major surgical procedures within 28 days or non-study-related minor procedures within 7 days of treatment.
- Prior therapy with KRASG12C (ON) inhibitor Other inclusion/exclusion criteria may apply.
π Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
π All Participating Trial Locations (64 Sites)
- Highlands Oncology Group β Springdale, Arkansas
- UC Irvine Cancer Center β Orange, California
- UC Davis Cancer Center β Sacramento, California
- UCSF β San Francisco, California
- University of Miami School of Medicine Sylvester Comprehensive Cancer Center β Miami, Florida
- Moffitt Cancer Center β Tampa, Florida
- American Oncology Partners of Maryland β Bethesda, Maryland
- Dana-Farber Cancer Institute β Boston, Massachusetts
- Roswell Park Comprehensive Cancer Center β Buffalo, New York
- MSK Cancer Center β New York, New York
- Columbia University Irving Medical Center β New York, New York
- Tennessee Oncology β Nashville, Tennessee
- Next Oncology β San Antonio, Texas
- START β San Antonio, Texas
- Next Oncology Virginia β Fairfax, Virginia
- Southside Cancer Care Centre β Sydney, New South Wales
- Peninsula & South Eastern Haematology and Oncology Group β Frankston, Victoria
- Austin Health, Olivia Newton-John Cancer Research & Wellness Centre β Heidelberg, Victoria
- South West Health Care β Warrnambool, Victoria
- NH Hospital a.s. β HoΕovice,
- Klinika onkologie a radioterapie, Fakultni Nemocnice Hradec Kralove β Hradec KrΓ‘lovΓ©,
- Onkologicka klinika, Fakultni Nemocnice Olomouc β Olomouc,
- ICO β Angers,
- CHU Bordeaux Hospital Saint-Andre β Bordeaux,
- Centre Jean Perrin β Clermont-Ferrand,
π° Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.